文章：

接受二线或三线来那度胺或硼替佐米治疗的复发/难治性多发性骨髓瘤患者生活质量的前瞻性纵向研究

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment

原文发布日期：2017-03-17

DOI: 10.1038/bcj.2017.20

类型: Original Article

开放获取: 是

英文摘要：

Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients’ health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational study at different time points. At baseline, patients in the lenalidomide cohort were frailer than in the bortezomib cohort with more rapid disease progression at study entry (more patients with Eastern Cooperative Oncology Group performance status >2, shorter time from diagnosis, more chronic heart failure, higher serum creatinine levels, more patients with dialysis required). About 40% of the patients receiving lenalidomide discontinued the study in <6 months while 55% in the bortezomib cohort discontinued. No substantial HRQoL deterioration was observed for the first 6 months in patients with RRMM receiving one or the other treatment. For patients still on treatment at study completion (month 6), only the European Organization for Research and Treatment of Cancer Quality-of-Life Core domains of Diarrhoea and Global Health Status/QoL had worsened in the lenalidomide and bortezomib cohorts, respectively. A clinically meaningful deterioration in HRQoL was more often observed for patients who discontinued the study prior to 6 months in the bortezomib cohort than in the lenalidomide cohort.

摘要翻译： 

多发性骨髓瘤治疗进展显著延长了患者生存期，这凸显了在临床研究中评估患者健康相关生活质量的重要性。一项欧洲前瞻性多中心观察性研究，在不同时间点测量了接受二线或三线来那度胺或硼替佐米治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量/功能状态及症状。基线数据显示，来那度胺组患者相较于硼替佐米组更为虚弱，入组时疾病进展更迅速（美国东部肿瘤协作组体能状态＞2分者更多、确诊至入组时间更短、慢性心力衰竭发生率更高、血清肌酐水平更高、需要透析者更多）。来那度胺组约40%患者在6个月内中止研究，而硼替佐米组这一比例为55%。在治疗最初6个月内，两组复发/难治性多发性骨髓瘤患者均未出现显著的HRQoL恶化。对于完成6个月研究时仍在治疗的患者，来那度胺组与硼替佐米组分别仅在欧洲癌症研究与治疗组织生活质量核心问卷的腹泻维度、总体健康状况/生活质量维度出现恶化。在硼替佐米组中，未满6个月提前退出研究的患者出现具有临床意义的HRQoL恶化的情况较来那度胺组更为常见。

原文链接：

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment